Adicet Bio, a privately held preclinical biotech looking to move ahead its “off-the-shelf” CAR-T cell therapies, has struck a deal with struggling resTORbio to use its Nasdaq listing as a backdoor to the public markets.
The companies on Wednesday announced an agreement to combine in a type of transaction sometimes referred to as a “reverse merger.”
Earlier this year Boston-based resTORbio (NASDAQ: TORC) announced it was seeking someone to buy the firm or strike a deal for its technology. That decision was made following the November failure of its lead drug in a pivotal trial treating lung infections in… Read more »
UNDERWRITERS AND PARTNERS
